Sapient Appoints Jonathan Usuka as Chief Business Officer

In this role, Dr. Usuka will lead Sapient’s global business strategy for commercial collaborations, strategic partnerships, and client service innovations across its proteomic and metabolomic offerings leveraging Sapient’s Human Biology Database, the company’s industry leading real-world data asset. He will be the driving force in identifying new opportunities to serve therapeutic clients with Sapient’s large-scale multi-omics lab and unique data capabilities to enable advances in disease prediction, drug development, diagnostics, and personalized treatments for patients.

“We are absolutely thrilled to welcome Jonathan into this critical leadership role for Sapient,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “He is a rare talent possessing both deep scientific acumen and extensive experience in business development and growth strategy, particularly in applying data and informatics to accelerate biopharma R&D. His expertise aligns perfectly with our integrated discovery approach and focus on turning data into biological insight that advances our clients’ drug discovery and development pipelines. Jonathan’s visionary perspective and practical understanding of our market’s needs will ensure we are well-poised to help biopharma capitalize on the enormous potential of multi-omics – for example, with our proteomics methods that measure among the most biologically important proteins at unprecedented depth and speed.”

Dr. Usuka’s deep experience in business and scientific leadership in the pharmaceutical industry spans more than 25 years. He joins Sapient from REALM IDx, where he led the creation and launch of integrated diagnostics in pharmaceutical services and pivoted the company to profitability, resulting in a successful exit to strategic and private equity investors. Previously, Dr. Usuka was a Senior Expert at McKinsey & Company, leading their Center for Analytics and Real-world Evidence. In that role he served pharmaceutical industry leaders in advancing their therapeutic pipelines through AI and supported M&A strategy for private equity investors in pharmaceutical services. He has also held senior roles at top pharmaceutical companies including as Director, R&D Informatics at Celgene and as Director, Global R&D Information at Roche. Dr. Usuka earned a PhD in Chemistry and was an NIH Fellow in Genetics at Stanford University’s School of Medicine, and holds an MBA in Finance from The Wharton School, University of Pennsylvania and a BA from Princeton University.

“Sapient has an amazing group of scientists and a technology approach that can revolutionize the discovery and development of novel therapeutics, and I’m honored to join in that pursuit,” said Dr. Usuka. “The company is uniquely positioned with high throughput proteomics and metabolomics capabilities for generating multi-omics data at population scale, offering the analytical power to go beyond the genome to achieve robust biological discoveries that can be rapidly translated for clinical impact. I’m excited to help our pharmaceutical and biotech clients to accelerate their discovery and development programs through this several orders of magnitude increase in throughput and accuracy in proteomics services. Together with our expert biocomputational capabilities, we will drive to actionable insights for therapeutic decisions, help translate discoveries into the clinic, and have a transformational impact on patients.”

###

About Sapient
Sapient is a leading biomarker discovery organization providing bespoke, at scale services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time.

These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data; robust quality control analysis; and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases. For more information, visit sapient.bio.

Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010